• Monopar Therapeutics' (MNPR) "Overweight" Rating Reaffirmed at Piper Sandler

    Source: Buzz FX / 20 Mar 2025 07:16:17   America/Chicago


    Monopar Therapeutics' (MNPR) "Overweight" Rating Reaffirmed at Piper Sandler Written by MarketBeat March 20, 2025 Share Link copied to clipboard. Remove Ads Monopar Therapeutics ( NASDAQ:MNPR - Get Free Report ) 's stock had its "overweight
    Read more...
Share on,